Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05884775 · ClinicalTrials.gov registry record · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
A NA study of Type 2 Diabetes, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 353
- Enrollment target
- 1
- Study location
NCT05884775 is a NA study of Type 2 Diabetes that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 353 participants, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05884775, a NA study of Type 2 Diabetes, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 353 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).
Conditions Studied
Interventions
- OTHER Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05884775
The ClinicalTrials.gov registry entry for NCT05884775 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (68% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool is the first listed.
NCT05884775 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05884775 about?
NCT05884775 is a clinical study titled "Novel Digital Patient-Reported Outcomes Tool for Diabetes Management". Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).
What is the current status of trial NCT05884775?
This trial is currently recruiting. It is a NA study. The enrollment target is 353 participants. The study started on 2025-11-04. Estimated completion is 2028-05-31.
What conditions does trial NCT05884775 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05884775?
The interventions under investigation include: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool (OTHER).
Who is sponsoring clinical trial NCT05884775?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05884775 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.